Mascarenhas J - Search Results

1

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.

Mascarenhas J, Baer MR, Kessler C, Hexner E, Tremblay D, Price L, Sandy L, Weinberg R, Pahl H, Silverman LR, Goldberg JD, Kosiorek H, Dueck AC, Hoffman R. Mascarenhas J, et al. Leuk Lymphoma. 2019 May;60(5):1343-1345. doi: 10.1080/10428194.2018.1532509. Epub 2019 Jan 22. Leuk Lymphoma. 2019. PMID: 30668266 Free PMC article. Clinical Trial. No abstract available.

2

Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders.

Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, Wisch N, Xu M. Ishii T, et al. Among authors: mascarenhas j. Blood. 2009 Jun 4;113(23):5942-50. doi: 10.1182/blood-2008-09-179416. Epub 2009 Feb 4. Blood. 2009. PMID: 19196660 Free article.

3

The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.

Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. Sozer S, et al. Among authors: mascarenhas j. Blood. 2009 May 21;113(21):5246-9. doi: 10.1182/blood-2008-11-191544. Epub 2009 Mar 17. Blood. 2009. PMID: 19293426 Free PMC article.

4

Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.

Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, Najfeld V, Zhao ZJ, Hoffman R, Wisch N, Xu M. Wang J, et al. Among authors: mascarenhas j. Leukemia. 2009 Sep;23(9):1577-86. doi: 10.1038/leu.2009.85. Epub 2009 Apr 23. Leukemia. 2009. PMID: 19387466

5

Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.

Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V. Wang X, et al. Among authors: mascarenhas j. Exp Hematol. 2009 Oct;37(10):1194-200. doi: 10.1016/j.exphem.2009.07.003. Epub 2009 Jul 15. Exp Hematol. 2009. PMID: 19615425 Free article.

6

Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.

Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, Mascarenhas J, Xu M, Hoffman R. Lu M, et al. Among authors: mascarenhas j. Exp Hematol. 2010 Jun;38(6):472-80. doi: 10.1016/j.exphem.2010.03.005. Epub 2010 Mar 18. Exp Hematol. 2010. PMID: 20303384 Free PMC article.

7

The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms.

Cho SY, Xu M, Roboz J, Lu M, Mascarenhas J, Hoffman R. Cho SY, et al. Among authors: mascarenhas j. Cancer Res. 2010 Apr 15;70(8):3402-10. doi: 10.1158/0008-5472.CAN-09-3977. Epub 2010 Apr 13. Cancer Res. 2010. PMID: 20388788

8

Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.

Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J, Xu M, Hoffman R. Lu M, et al. Among authors: mascarenhas j. Blood. 2010 Nov 18;116(20):4284-7. doi: 10.1182/blood-2010-04-279125. Epub 2010 Jul 12. Blood. 2010. PMID: 20625010 Free PMC article.

9

Therapeutic options for patients with myelofibrosis in blast phase.

Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R. Mascarenhas J, et al. Leuk Res. 2010 Sep;34(9):1246-9. doi: 10.1016/j.leukres.2010.05.008. Leuk Res. 2010. PMID: 20627294

10

Myeloproliferative neoplasms: new translational therapies.

Mascarenhas J, Hoffman R. Mascarenhas J, et al. Mt Sinai J Med. 2010 Nov-Dec;77(6):667-83. doi: 10.1002/msj.20225. Mt Sinai J Med. 2010. PMID: 21105128 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

558 results

Search Page